The invention relates to composite antigens comprising an antigen obtained or derived from an antigenic epitope of one or more pathogens that induces an immune response in a mammal, an antigen obtained or derived from bacterial cell wall material that induces an immune response in a mammal such as LTA, PNG or LPS, and a T cell stimulating antigen such as CRM. Preferably the composite antigen comprises an immunogenic composition or a vaccine that is effective against the pathogen or can generate antibodies that can be collected that are protective against infection by the pathogen. In addition, the invention relates to vaccines comprising composite antigens and to method for treating and preventing an infection.

Combinations of probiotic compositions are described which are beneficial for human hosts in reducing gas and bloating, stomach acidity, and constipation also capable of boosting the immune capacity. The compositions comprise blends including B. coagulans, B. subtilis, and B. clausii in combination with magnesium stearate, magnesium hydroxide, and simethicone. The combination probiotic compositions of the present invention behave in a synergistic manner in their nature of action both in-vitro and in-vivo. The combination probiotic compositions of the present invention are also very stable for comparatively greater amounts of time period.

Combinations of probiotic compositions are described which are beneficial for human hosts in reducing gas and bloating, stomach acidity, and constipation also capable of boosting the immune capacity. The compositions comprise blends including B. coagulans, B. subtilis, and B. clausii in combination with magnesium stearate, magnesium hydroxide, and simethicone. The combination probiotic compositions of the present invention behave in a synergistic manner in their nature of action both in-vitro and in-vivo. The combination probiotic compositions of the present invention are also very stable for comparatively greater amounts of time period.

Technologies for the prevention and/or treatment of nosocomial infections.

Provided herein are isolated proteins isolatable from a Klebsiella spp. Also provided are compositions that include one or more of the proteins, and methods for making and methods for using the proteins.

The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides from Streptococcus pneumoniae bacterial capsules are conjugated to a carrier protein in an aprotic solvent such as dimethylsulfoxide (DMSO). The present invention also provides methods for providing an enhanced immune response to a pneumococcal polysaccharide protein conjugate vaccine comprising administering to a human subject an immunogenic composition comprising polysaccharide-protein conjugates prepared in DMSO conditions.

The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides from Streptococcus pneumoniae bacterial capsules are conjugated to a carrier protein in an aprotic solvent such as dimethylsulfoxide (DMSO). The present invention also provides methods for providing an enhanced immune response to a pneumococcal polysaccharide protein conjugate vaccine comprising administering to a human subject an immunogenic composition comprising polysaccharide-protein conjugates prepared in DMSO conditions.

The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides from Streptococcus pneumoniae bacterial capsules are conjugated to a carrier protein in an aprotic solvent such as dimethylsulfoxide (DMSO). The present invention also provides methods for providing an enhanced immune response to a pneumococcal polysaccharide protein conjugate vaccine comprising administering to a human subject an immunogenic composition comprising polysaccharide-protein conjugates prepared in DMSO conditions.

The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides from Streptococcus pneumoniae bacterial capsules are conjugated to a carrier protein in an aprotic solvent such as dimethylsulfoxide (DMSO). The present invention also provides methods for providing an enhanced immune response to a pneumococcal polysaccharide protein conjugate vaccine comprising administering to a human subject an immunogenic composition comprising polysaccharide-protein conjugates prepared in DMSO conditions.

A multivalent immunogenic composition is provided, including one or more recombinant proteins selected from the group consisting of a recombinant attenuated Staphylococcus pseudintermedius Protein A (SEQ ID NO:2), a recombinant attenuated Staphylococcus pseudintermedius Leukotoxin S (SEQ ID NO:4), a recombinant attenuated Staphylococcus pseudintermedius Nucleotidase adenosine synthase protein (AdsA) (SEQ ID NO:6), a recombinant attenuated Staphylococcus pseudintermedius coagulase (SEQ ID NO:8), a recombinant attenuated Staphylococcus pseudintermedius Leukotoxin F (SEQ ID NO: 10), and a recombinant attenuated Staphylococcus pseudintermedius exotoxin 15 (SEQ ID NO: 12). Synthetic genes expressing the attenuated recombinant proteins and optimized for expression in E. coli are provided. Vaccines and therapeutic compositions comprising the one or more recombinant proteins are provided.